For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start. The SPDR S&P Biotech Index ETF, an industry benchmark, has climbed 34% over the trailing-12-month period, nearly three times the gains of the S&P 500.
These two drugmakers that have done particularly well for themselves. Moreover, both companies expect catalysts that could send their results even higher. Let’s consider whether that makes either stock a buy.
This post originally appeared at The Motley Fool.